Calcitonin Gene-Related Peptide (CGRP): What It Is and How It Works

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide that plays a central role in migraine. It is released by sensory nerves, causes blood vessels to dilate, and helps transmit pain signals. Elevated CGRP levels are consistently found during migraine attacks, which is why CGRP has become the target of a major class of migraine medications.

What Is Calcitonin Gene-Related Peptide?

CGRP is produced throughout the nervous system. It is especially abundant in the trigeminal ganglion, a cluster of nerves that supplies sensation to the face and head. The peptide was named after the calcitonin gene because it was first identified as an alternative product of that gene. However, CGRP is not the same as calcitonin; it has entirely different functions in the body.

Some people confuse CGRP with parathyroid related peptide, another signaling molecule that shares some structural similarities. Parathyroid related peptide primarily regulates bone and calcium metabolism, while CGRP is best known for its role in pain and migraine. Both are examples of how the body uses short chains of amino acids to send precise chemical messages.

How CGRP Drives Migraine and Other Pain Conditions

During a migraine attack, CGRP is released from activated trigeminal nerve endings. The peptide then binds to CGRP receptors on blood vessels and other cells. This binding causes vasodilation, or widening of blood vessels, in the meninges — the protective layers around the brain. CGRP also sensitizes nerve endings, making them more responsive to pain.

This process is called peripheral sensitization. If it continues, it can lead to central sensitization, where the brain itself becomes more sensitive to pain signals. That is why early treatment of a migraine attack may be more effective. CGRP is also implicated in cluster headache and some other pain disorders, though its exact role in those conditions is still being studied.

Calcitonin Gene-Related Peptide Medications: A New Era for Migraine

Two main classes of prescription drugs target the CGRP pathway: monoclonal antibodies and gepants. Monoclonal antibodies are large proteins that bind either CGRP itself or its receptor. Gepants are small molecules that block the CGRP receptor. Both approaches reduce the effects of CGRP and can prevent or treat migraine attacks.

These calcitonin gene-related peptide medications are available only by prescription in the United States. They are not the same as natural peptide supplements, which are sold over the counter and are not FDA-approved for migraine. Many consumers ask are peptide supplements safe for migraine prevention; the honest answer is that most lack rigorous clinical trial evidence, whereas CGRP-targeted drugs have been studied in large randomized trials.

CGRP vs. Other Peptides in Medicine

CGRP is not the only peptide with medical importance. The success of CGRP inhibitors has spurred interest in the broader peptide therapeutics field. For example, peptide drug conjugates combine a targeting peptide with a therapeutic payload to deliver treatment more precisely to specific cells. This approach is being explored in cancer and other diseases.

Other peptides are used as biomarkers or drug targets in bone disorders. The number of peptide-based therapies continues to grow as scientists learn how to stabilize and deliver these molecules effectively.

Safety and Side Effects of CGRP-Targeted Treatments

CGRP monoclonal antibodies and gepants are generally well tolerated. Common side effects include injection site reactions for the antibodies, and constipation, nausea, or fatigue for gepants. Serious side effects are rare but can include hypersensitivity reactions and, in some cases, increases in blood pressure.

Because CGRP is involved in cardiovascular function, people with certain heart conditions should discuss the risks and benefits with a healthcare professional. CGRP-targeted medications are not recommended during pregnancy or breastfeeding unless clearly needed. Always consult a doctor before starting or stopping any migraine treatment.

Key Takeaways

• Calcitonin gene-related peptide is a neuropeptide that plays a central role in migraine pathophysiology.
• CGRP causes vasodilation and nerve sensitization, which contribute to migraine pain.
• Two main classes of prescription drugs target CGRP: monoclonal antibodies and gepants.
• CGRP monoclonal antibodies are FDA-approved for migraine prevention in the United States.
• Gepants are small-molecule CGRP receptor antagonists used for acute and preventive migraine treatment.
• Natural peptide supplements are not FDA-approved for migraine and should not replace prescribed therapy.
• Consult a healthcare professional before making any changes to your migraine treatment plan.